Hetero biaryl derivatives as matrix metalloproteinase...

Details Hetero biaryl derivatives as matrix metalloproteinase... Hetero biaryl derivatives as matrix metalloproteinase...

2007-02-20

2007-02-20

Balasubramanian, Venkataraman (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S341000, C514S342000, C546S268100, C546S268400

Reexamination Certificate

active

10634709

ABSTRACT:
This invention provides compounds defined by Formula Iand pharmaceutically acceptable salts thereof,and pharmaceutical compositions comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof, together with a pharmaceutically acceptable carrier, diluent, or excipient. The invention also provides methods of treating osteo- and rheumatoid arthritis.

REFERENCES:
patent: 5130317 (1992-07-01), Baader et al.
patent: 5260323 (1993-11-01), Baader et al.
patent: 5519038 (1996-05-01), Baader et al.
patent: 5756524 (1998-05-01), Riordan et al.
patent: 6008243 (1999-12-01), Bender et al.
patent: 6150394 (2000-11-01), Fumihiko et al.
patent: 6172057 (2001-01-01), Aranapakam et al.
patent: 6656932 (2003-12-01), Picard et al.
patent: 2002/0151555 (2002-10-01), Barvian et al.
patent: 2002/0151558 (2002-10-01), Andrianjara et al.
patent: 2002/0156061 (2002-10-01), Barvian et al.
patent: 2002/0156069 (2002-10-01), Picard et al.
patent: 2002/0161000 (2002-10-01), Barvian et al.
patent: 2002/0193377 (2002-12-01), Andrianjara et al.
patent: 2003/0004172 (2003-01-01), Harter et al.
patent: 2003/0078276 (2003-04-01), Andrianjara et al.
patent: 2003/0087924 (2003-05-01), Sorenson
patent: 2003/0130278 (2003-07-01), Gaudilliere et al.
patent: 2003/0144274 (2003-07-01), Bunker et al.
patent: 2003/0216402 (2003-11-01), Gaudilliere et al.
patent: 2003/0220355 (2003-11-01), Gaudilliere et al.
patent: 2003/0229103 (2003-12-01), Weithmann et al.
patent: 2004/0006077 (2004-01-01), Gaudilliere et al.
patent: 2082076 (1993-05-01), None
patent: 0286364 (1994-07-01), None
patent: 0935963 (1999-08-01), None
patent: 1138680 (2001-10-01), None
patent: 1388341 (2004-02-01), None
patent: 10195063 (1998-07-01), None
patent: 11-349572 (1999-12-01), None
patent: WO-00/09485 (2000-02-01), None
patent: WO 00/31063 (2000-06-01), None
patent: WO-01/12611 (2001-02-01), None
patent: WO-01/12612 (2001-02-01), None
patent: WO-01/63244 (2001-08-01), None
patent: WO-02/34726 (2002-05-01), None
patent: WO02/34753 (2002-05-01), None
patent: WO 02/45703 (2002-06-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064080 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064547 (2002-08-01), None
patent: WO 02/064568 (2002-08-01), None
patent: WO 02/064571 (2002-08-01), None
patent: WO 02/064572 (2002-08-01), None
patent: WO 02/064578 (2002-08-01), None
patent: WO 02/064595 (2002-08-01), None
patent: WO 02/064598 (2002-08-01), None
patent: WO 02/064599 (2002-08-01), None
patent: WO 03/006456 (2003-01-01), None
patent: WO 03/015776 (2003-02-01), None
patent: WO 03/032999 (2003-04-01), None
patent: WO 03/033478 (2003-04-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 03/076417 (2003-09-01), None
patent: WO 04/000322 (2003-12-01), None
U.S. Appl. No. 10/071,032, filed Feb. 8, 2002, Dyer et al.
U.S. Appl. No. 10/634,531, filed Aug. 5, 2003, Johnson.
U.S. Appl. No. 10/634,162, filed Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,473, Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,289, Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,180, Aug. 5, 2003, Bunker et al.
U.S. Appl. No. 10/634,712, Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,181, Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,489, Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,420, Aug. 5, 2003, Roark.
U.S. Appl. No. 10/634,716, Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,288, Aug. 5, 2003, O'Brien.
U.S. Appl. No. 10/634,717, Aug. 5, 2003, Nahra et al.
U.S. Appl. No. 10/634,177, Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,290, Aug. 5, 2003, Wilson.
U.S. Appl. No. 10/634,182, Aug. 5, 2003, Li.
U.S. Appl. No. 10/634,419, Aug. 5, 2003, Hicks et al.
U.S. Appl. No. 10/634,713, Aug. 5, 2003, Picard.
U.S. Appl. No. 10/634,225, Aug. 5, 2003, Picard et al.
U.S. Appl. No. 10/634,718, Aug. 5, 2003, Ortwine.
U.S. Appl. No. 10/739,261, Dec. 18, 2003, Bunker et al.
Billinghurst, et al, “Comparison of the Degradation of Type II Collagen and Proteoglycan in Nasal and Articular Cartilages Induced by Interleukin-1 and the Selective Inhibition of Type II Collagen Cleavage by Collagenase”, Arthritis & Rheumatism, vol. 43, No. 3 Mar. 2000, pp. 664-672.
Dahlberg, et al, “Selective Enhancement of Collagenase-Mediated Cleavage of Resident Type II Collagen in Cultured Osteoarthritic Cartilage and Arrest with a Synthetic Inhibitor That Spares Collagenase 1 (Matrix Metalloproteinase 1)”, Arthritis & Rheumatism, vol. 43, No. 3, Mar. 2000 pp. 673-682.
Freemont, et al, “In situ zymographic localisation of type II collagen degrading activity in osteoarthritic human articular cartilage”, Ann. Rheum. Dis. 1999, 58, pp. 357-365.
Hirota, et al, “Novel Synthesis of Pyrido[3,4-d]Pyrimidines, Pyrido[2,3-d]-Pyrimidines and Quinazolones via Palladium-Catalyzed Oxidative Coupling”, Heterocycles, vol. 37, No. 1, 1994 pp. 563-570.
Reboul, et al, “The New Collagenase, Collagenase-3, Is Expressed and Synthesized by Human Chondrocytes but not by Synoviocytes”, J. Clin. Invest. vol. 97, No. 9, May 1996 pp. 2011-2019.
Wernicke, et al, “Cloning of Collageanse 3 from the Synovial Membrane and Its Expression In Rheumatiod Arthritis and Osteoarthritis”, J. of Rheumatology, 1996, vol. 23, No. 4, pp. 590-595.
Chen, et al, “Structure-Based Design of a Novel, Potent, and Selective Inhibitor for MMP-13 Utilizing NMR Spectroscopy and Computer-Aided Molecular Design”, J. Am. Chem. Soc., 2000, vol. 122, pp. 9648-9654.
Billinghurst, et al, “Enhanced Cleavage of Type II Collagen by Collagenase in Osteoarthritic Articular Cartilage”, J. Clin. Invest., vol. 99, No. 7, Apr. 1997, pp. 1534-1545.
Lovejoy, et al, “Crystal structures of MMP-1 and -13 reveal the structural basis for selectivity of collagenase inhibitors”, Nature Structural Biology, vol. 6, No. 3, Mar. 1999, pp. 217-221.
Moy, et al, “High-resolution Solution Structure of the Catalytic Fragment of Human Collagenase-3 (MMP-13) Complexed with a Hydroxamic Acid Inhibitor”, J. Mol. Biol., 2000, vol. 302, pp. 671-689.
Neuhold, et al, “Postnatal expression in hyaline cartilage of constitutively active human collagenase-3 (MMP-13) induces osteoarthritis in mice” J. Clin. Invest. Jan. 2001, vol. 107, No. 1 pp. 35-44.
Mitchell, et al, “Cloning, Expression, and Type II Collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage”, J. Clin. Invest., vol. 97, No. 3, Feb. 1996 pp. 761-768.
International Search Report in PCT/IB03/03616.
Chemical Abstracts Nakayama, et al, “Preparation of 2-ethynylthiazole derivatives as leukotriene antagonists” AN 129:189329.
Robert et al., “Non-acidic antiinflammatory compounds II. Synthesis and activity of 6-amino-2,4-lutidine derivatives”, Eur. J. Med. Chem., vol. 29, 1994, pp. 841-854.
Office Action mailed Jun. 16, 2003, in U.S. Appl. No. 10/264,764.
Berthel et al., “Identification of phenyl-pyridine-2-carboxylic acid derivatives as novel cell cycle inhibitors with increased selectivity for cancer cells”, Anticancer Drugs, vol. 13, 2002, pp. 359-366.

Affiliated with

Also associated with

Rating

Hetero biaryl derivatives as matrix metalloproteinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hetero biaryl derivatives as matrix metalloproteinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hetero biaryl derivatives as matrix metalloproteinase... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3845883